Latest news and press releases about Bolt Biotherapeutics, Inc. (BOLT): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2).
Price
| Price | $3.35 |
| Market Cap | $6M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.45 |
| EV / EBITDA | -0.67 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -125.92% |
| Return on Invested Capital | -67.72% |
| Return on Assets | -58.81% |
| Gross Margin | 95.68% |
| Operating Margin | -623.04% |
| Net Margin | -611.47% |
Related companies: AEON · CING · CLRB · EVGN · IMNN · INAB · LYRA
Explore sector: Healthcare · Biotechnology
More sections of BOLT: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks